by CheckRare Staff | Feb 21, 2024
Davide Martino, MD, McMaster University Department of Medicine, discusses the BASIS clinical trial, a phase 3 study testing marstacimab in patients with hemophilia without inhibitors. Hemophilia is a bleeding disorder that slows the blood clotting...
by CheckRare Staff | Aug 21, 2023
Bob Lojewski, CSL Behring’s senior vice president and general manager of North America, talks about the changes in the treatment landscape for hemophilia B, including the recent use of gene therapy. Hemophilia B is a rare bleeding disorder caused by...
by Madaline Spencer | Apr 11, 2023
Rob Schroeder, a patient with hemophilia B describes his experience receiving gene therapy (etranacogene dezaparvovec). Hemophilia B is a genetic bleeding disorder due to dysfunction or deficiency of coagulation Factor IX. People with this condition may bleed...
by Peter Ciszewski | Dec 2, 2022
Steven Pipe, MD, Professor of Pediatrics and Pathology, and Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program at the University of Michigan, discusses the results of the phase III HOPE-B clinical trial that led to the recent FDA...
by Peter Ciszewski | Apr 14, 2022
Steven Pipe, MD, Professor of Pediatrics and Pathology, and Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program at the University of Michigan, discusses the recent announcement of positive long-term results from the phase 3 HOPE-B...
